AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9362437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (120 mg, 2-hour infusion)
Number of subjects: 86
Study 1328567 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg once a day) for 8 days
Number of subjects: 0
Study 1328567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (5 mg/day) and Captopril (25 mg/day) for 6 weeks
Number of subjects: 0
Study 1328567 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 1328567 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg once a day) and Nitrendipine (20 mg once a day)
Number of subjects: 0
Study 3900591 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan plus Prednisone (M.P.) X 6 monthly cycles
Number of subjects: 133
Study 3900591 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine plus Melphalan plus Cyclophosphamide plus Prednisone (VMCP) X 6 monthly cycles
Number of subjects: 133
Study 3900591 — intervention group
Group type: COMPARATOR
Intervention: Peptichemio, Cyclophosphamide, BCNU (third schedule)
Number of subjects: 133
Study 3900591 — intervention group
Group type: EXPERIMENTAL
Intervention: MP and VCMP arms
Number of subjects: 133
Study 3900591 — intervention group
Group type: EXPERIMENTAL
Intervention: Response (M. spike reduction greater than 75%)
Number of subjects: 133
Study 31201808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice packs, Tylenol, and Toradol postoperative pain regimen
Number of subjects: 63
Study 31201808 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative pain regimen
Number of subjects: 63
Study 29169840 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfaxalone (2 mg kg−1) with fentanyl (2 μg kg−1) for induction and alfaxalone variable rate infusion (VRI) combined with fentanyl constant rate infusion (CRI) (10 μg kg−1 hour−1) for maintenance (group AF)
Number of subjects: 12
Study 29169840 — intervention group
Group type: COMPARATOR
Intervention: Alfaxalone (2 mg kg−1) for induction and alfaxalone variable rate infusion (VRI) (0.15 mg kg−1 minute−1) for maintenance (group AP)
Number of subjects: 12
Study 26422723 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 606
Study 26422723 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 75 mg
Number of subjects: 606
Study 26422723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 606
Study 26422723 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 606
Study 24063556 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention
Number of subjects: 300
Study 24063556 — intervention group
Group type: COMPARATOR
Intervention: Treatment-As-Usual
Number of subjects: 300
Study 21256897 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 83
Study 21256897 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TSST
Number of subjects: 83
Study 19587126 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fruit and -vegetable diets (mean intake: 6.1 servings/d of fruits and vegetables, 2.7 mg/d of lutein and zeaxanthin)
Number of subjects: 394
Study 19587126 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (standard diet, mean intake: 4.6 servings/d of fruits and vegetables, 2.1 mg/d of lutein and zeaxanthin)
Number of subjects: 394
Study 19587126 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake of lutein and zeaxanthin (highest quintile, median 6.4 mg/d)
Number of subjects: 394
Study 17893930 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education and counseling intervention
Number of subjects: 115
Study 17893930 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 115
Study 15203438 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 37
Study 15203438 — intervention group
Group type: COMPARATOR
Intervention: Chlormethiazole (CMZ)
Number of subjects: 37
Study 15203438 — intervention group
Group type: COMPARATOR
Intervention: Both CBZ and CMZ
Number of subjects: 37
Study 11589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/d
Number of subjects: 4056
Study 11589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 120 mg/d
Number of subjects: 4056
Study 11589267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4056
Study 11589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg/d in women with BMI >26.4 kg/m2
Number of subjects: 4056
Study 11589267 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 120 mg/d in women with BMI >26.4 kg/m2
Number of subjects: 4056
Study 11589267 — intervention group
Group type: COMPARATOR
Intervention: Placebo in women with BMI >26.4 kg/m2
Number of subjects: 4056
Study 9846035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (acute treatment)
Number of subjects: 38
Study 9846035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (chronic treatment)
Number of subjects: 38
Study 9846035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (acute treatment)
Number of subjects: 38
Study 9846035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (chronic treatment)
Number of subjects: 38
Study 8595647 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2342
Study 8595647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2342
Study 2760246 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic mouthrinse (Listerine Antiseptic)
Number of subjects: 83
Study 2760246 — intervention group
Group type: COMPARATOR
Intervention: 5% hydroalcohol control
Number of subjects: 83
Study 68272 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 318
Study 68272 — intervention group
Group type: COMPARATOR
Intervention: Radiology
Number of subjects: 318
Study 30586136 — intervention group
Group type: EXPERIMENTAL
Intervention: Template-guided lung nodule localization
Number of subjects: 213
Study 30586136 — intervention group
Group type: COMPARATOR
Intervention: CT-guided lung nodule localization
Number of subjects: 213
Study 28259517 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spine manipulation (TSM)
Number of subjects: 61
Study 28259517 — intervention group
Group type: COMPARATOR
Intervention: Sham thoracic spine manipulation (sham-TSM)
Number of subjects: 61
Study 28259517 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 61
Study 25601483 — intervention group
Group type: EXPERIMENTAL
Intervention: MILE program (Center MILE)
Number of subjects: 60
Study 25601483 — intervention group
Group type: EXPERIMENTAL
Intervention: MILE program (Community MILE)
Number of subjects: 60
Study 25601483 — intervention group
Group type: COMPARATOR
Intervention: Parent Instruction
Number of subjects: 60
Study 23702942 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained deep inspiration (5 seconds, 3 sets of 10 repetitions per day)
Number of subjects: 75
Study 23702942 — intervention group
Group type: COMPARATOR
Intervention: Control group (no breathing exercise)
Number of subjects: 75
Study 22233613 — intervention group
Group type: EXPERIMENTAL
Intervention: Inelastic arm bandages with pressure between 20-30 mmHg
Number of subjects: 78
Study 22233613 — intervention group
Group type: COMPARATOR
Intervention: Inelastic arm bandages with pressure between 44-68 mmHg
Number of subjects: 78
Study 22233613 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings (23-32 mmHg) for leg edema
Number of subjects: 78
Study 22233613 — intervention group
Group type: COMPARATOR
Intervention: Inelastic bandages (53-88 mmHg) for leg edema
Number of subjects: 78
Study 19969159 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (circuit-based rehabilitation, 12 sessions)
Number of subjects: 58
Study 19969159 — intervention group
Group type: COMPARATOR
Intervention: Control group (social and educational classes, comparable duration)
Number of subjects: 58
Study 17408917 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube feeding (TF) for 8 weeks, exclusively for 10 days and associated with meals thereafter, combined with psychotherapy, nutritional counseling, and a support group.
Number of subjects: 0
Study 17408917 — intervention group
Group type: COMPARATOR
Intervention: Control group received only psychotherapy, nutritional counseling, and a support group.
Number of subjects: 0
Study 15298072 — intervention group
Group type: EXPERIMENTAL
Intervention: GW-1000 (Sativex)
Number of subjects: 0
Study 11721260 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dynamic motion protocol
Number of subjects: 20
Study 11721260 — intervention group
Group type: COMPARATOR
Intervention: Immobilization (extension thumb spica cast for 3 weeks)
Number of subjects: 20
Study 9337187 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of bupivacaine (TEA, Th1 to Th5)
Number of subjects: 40
Study 9337187 — intervention group
Group type: COMPARATOR
Intervention: Standard anti‐anginal therapy (control group)
Number of subjects: 40
Study 7945741 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden, 4 mg
Number of subjects: 12
Study 7945741 — intervention group
Group type: EXPERIMENTAL
Intervention: Bornaprine, 4 mg
Number of subjects: 12
Study 7945741 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 2979234 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg kg‐1 h‐1 ranitidine
Number of subjects: 134
Study 2979234 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg kg‐1 h‐1 ranitidine
Number of subjects: 134
Study 28960312 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release niacin (2 g) with high-fat meals containing saturated fatty acids (SFAs)
Number of subjects: 16
Study 28960312 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release niacin (2 g) with high-fat meals containing monounsaturated fatty acids (MUFAs)
Number of subjects: 16
Study 28960312 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release niacin (2 g) with high-fat meals containing MUFAs plus omega-3 long-chain polyunsaturated fatty acids (LCPUFAs)
Number of subjects: 16
Study 28960312 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release niacin (2 g) with high-fat meals containing no fat
Number of subjects: 16
Study 28386699 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (100 mcg orally)
Number of subjects: 25
Study 28386699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28386699 — intervention group
Group type: EXPERIMENTAL
Intervention: LSD (100 mcg orally) with ketanserin (40 mg orally)
Number of subjects: 25
Study 26175218 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (1-3 ml) used for sealing the needle track (Group B)
Number of subjects: 322
Study 26175218 — intervention group
Group type: COMPARATOR
Intervention: No sealing with normal saline (Group A)
Number of subjects: 322
Study 26175218 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline (Group B)
Number of subjects: 322
Study 23352180 — intervention group
Group type: EXPERIMENTAL
Intervention: Long's manipulation (LM)
Number of subjects: 0
Study 23352180 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese Massage (TCM)
Number of subjects: 0
Study 21290982 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating/rotating power toothbrush (Oral‐B Precision Clean)
Number of subjects: 0
Study 21290982 — intervention group
Group type: COMPARATOR
Intervention: ADA reference manual toothbrush
Number of subjects: 0
Study 18719035 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced CT angiography (CTA) and CT perfusion (CTP)
Number of subjects: 198
Study 16531904 — intervention group
Group type: EXPERIMENTAL
Intervention: CBEX (chicken breast extract)
Number of subjects: 8
Study 16531904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16531904 — intervention group
Group type: EXPERIMENTAL
Intervention: CBEX
Number of subjects: 8
Study 13680085 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg methylphenidate
Number of subjects: 11
Study 13680085 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 mg/kg methylphenidate
Number of subjects: 11
Study 13680085 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.60 mg/kg methylphenidate
Number of subjects: 11
Study 13680085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11084468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone
Number of subjects: 88
Study 11084468 — intervention group
Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 88
Study 9187188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure triggering of -0.5 cm H2O
Number of subjects: 10
Study 9187188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure triggering of -1 cm H2O
Number of subjects: 10
Study 9187188 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow triggering of 5/2 L/min
Number of subjects: 10
Study 9187188 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow triggering of 10/3 L/min
Number of subjects: 10
Study 8068446 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (300 mg/daily for 5 days)
Number of subjects: 27
Study 8068446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/daily for 5 days) after clodronate in 7 relapsing patients
Number of subjects: 27
Study 8068446 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg/daily for 5 days) in 8 newly diagnosed patients
Number of subjects: 27
Study 3195851 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP-choline (100 mg/kg/day for seven days)
Number of subjects: 24
Study 3195851 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 8836 — intervention group
Group type: EXPERIMENTAL
Intervention: Benorylate suspension for 7 days
Number of subjects: 0
Study 8836 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 0
Study 31186120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (14 mg, once daily)
Number of subjects: 711
Study 31186120 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous liraglutide (1.8 mg, once daily)
Number of subjects: 711
Study 31186120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 711
Study 28513068 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 12 weeks
Number of subjects: 80
Study 28513068 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for 12 weeks
Number of subjects: 80
Study 28513068 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 80
Study 26186140 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant gliadins (after reduction/alkylation)
Number of subjects: 0
Study 26186140 — intervention group
Group type: COMPARATOR
Intervention: Natural gliadins (before and after reduction/alkylation)
Number of subjects: 0
Study 26186140 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal domains of alpha- and gamma-gliadins
Number of subjects: 0
Study 26186140 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal domains of alpha- and gamma-gliadins
Number of subjects: 0
Study 26186140 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfide bonds
Number of subjects: 0
Study 23871794 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 31
Study 23871794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (general)
Number of subjects: 31
Study 22152592 — intervention group
Group type: EXPERIMENTAL
Intervention: n-BiPAP
Number of subjects: 540
Study 22152592 — intervention group
Group type: COMPARATOR
Intervention: n-CPAP
Number of subjects: 540
Study 19480610 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine medicated plaster and pregabalin combination therapy
Number of subjects: 229
Study 19480610 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine medicated plaster monotherapy
Number of subjects: 229
Study 19480610 — intervention group
Group type: COMPARATOR
Intervention: Pregabalin monotherapy
Number of subjects: 229
Study 19480610 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine medicated plaster with continued pregabalin treatment
Number of subjects: 229
Study 16502855 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Japanese PHCS
Number of subjects: 1910
Study 14642015 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate treatment
Number of subjects: 109
Study 14642015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 14642015 — intervention group
Group type: COMPARATOR
Intervention: Normal comparisons
Number of subjects: 109
Study 10668716 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1a (12 mIU, subcutaneously three times a week for 6 months)
Number of subjects: 61
Study 10668716 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously three times a week for 6 months)
Number of subjects: 61
Study 10668716 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta-1a
Number of subjects: 61
Study 10668716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 7726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine 10 mg/day
Number of subjects: 72
Study 7726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine 20 mg/day
Number of subjects: 72
Study 7726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine 30 mg/day
Number of subjects: 72
Study 7726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine (all doses)
Number of subjects: 72
Study 2248067 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 20
Study 2248067 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 20
Study 7262795 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily interval therapy (alternating application of Jellin ointment or cream and their bases, n = 26)
Number of subjects: 71
Study 7262795 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy (application of Jellin ointment or cream alone, n = 24)
Number of subjects: 71
Study 7262795 — intervention group
Group type: COMPARATOR
Intervention: Weekly interval therapy (application of Jellin ointment or cream for 4 days followed by 3 days of the corresponding base, n = 21)
Number of subjects: 71
Study 7262795 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 71
Study 7262795 — intervention group
Group type: COMPARATOR
Intervention: Daily interval therapy
Number of subjects: 71
Study 7262795 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval therapy
Number of subjects: 71
Study 31710983 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music
Number of subjects: 320
Study 31710983 — intervention group
Group type: COMPARATOR
Intervention: Algorithmically generated music
Number of subjects: 320
Study 30845322 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid conjugate vaccine campaign
Number of subjects: 200
Study 30845322 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement activities (meetings, media outreach, community-based activities)
Number of subjects: 200
Study 30845322 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions (FGD) with trial staff and community members
Number of subjects: 200
Study 28135140 — intervention group
Group type: EXPERIMENTAL
Intervention: Previsit individualized communication coaching session with a question prompt list (QPL)
Number of subjects: 170
Study 28135140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 170
Study 26173731 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenting
Number of subjects: 0
Study 26173731 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 23958808 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB
Number of subjects: 60
Study 23958808 — intervention group
Group type: EXPERIMENTAL
Intervention: rMenB
Number of subjects: 60
Study 23958808 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB (control group)
Number of subjects: 60
Study 21252735 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar-guided tension-free vaginal mesh insertion
Number of subjects: 190
Study 21252735 — intervention group
Group type: COMPARATOR
Intervention: Conventional vaginal prolapse surgery
Number of subjects: 190
Study 19097910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral component
Number of subjects: 41
Study 19097910 — intervention group
Group type: COMPARATOR
Intervention: Uncemented femoral component
Number of subjects: 41
Study 17426211 — intervention group
Group type: EXPERIMENTAL
Intervention: Aid modality (small wheeled cart for oxygen canister)
Number of subjects: 60
Study 17426211 — intervention group
Group type: COMPARATOR
Intervention: No-Aid modality (carried on shoulder)
Number of subjects: 60
Study 15327808 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain with high pain-related disability
Number of subjects: 17543
Study 15327808 — intervention group
Group type: COMPARATOR
Intervention: Chronic pain with no or limited pain-related disability
Number of subjects: 17543
Study 11803600 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt 60
Number of subjects: 40
Study 11803600 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 MeV photons
Number of subjects: 40
Study 9923411 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg rhIL-11
Number of subjects: 80
Study 9923411 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/kg rhIL-11
Number of subjects: 80
Study 9923411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9923411 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11 (both doses)
Number of subjects: 80
Study 9923411 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-11
Number of subjects: 80
Study 9243145 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 54
Study 9243145 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 54
Study 2780120 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusion of cow's milk from diet
Number of subjects: 146
Study 2780120 — intervention group
Group type: COMPARATOR
Intervention: Control diet containing cow's milk
Number of subjects: 146